The fall has fast settled in and, after a very successful 6th Drug Development Symposium held in Paris, France on 1-2 July 2019, our eyes are now turned to the upcoming 14th PVRI meeting in Lima, Peru.
The scientific programme is receiving its final touches under the leadership of co-chairs Max Gassmann and Harm-Jan Bogaard and their superb scientific team composed of Werner Seeger, Elena Goncharova, David Montani, and Zhenguo Zhai, and Paul Corris. There will be several highlighted areas including, quite appropriately for the surrounding geographical venue, hypoxia and high altitude and signalling mechanisms involved in the development of pulmonary hypertension (PH), orphans among the orphan diseases within the spectrum of PAH (e.g. pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis), PH in neonates including bronchopulmonary dysplasia, infant and maternal health at high altitude, and upcoming novel therapies.
Please note that abstract submission is now open for this meeting, and I particularly encourage our young scientists to submit their work. As in previous years, a total of fifteen $500 Travel Awards will be granted to the most meritorious abstracts. In addition to some of the topics mentioned above, there will be an entire Plenary session focused on Global Health, a targeted area of interest and research for the PVRI for the next several years. As mentioned in my previous blog, this tripartite Global Registry initiative (PVRI GoDeep, GoGlobal and Global Health) will thrive to have pulmonary vascular diseases (PVD) recognised as a global disease burden by the World Health Organization (WHO) and other international bodies with a global health focus. Full details about the progress of our Global Registry will be provided at the meeting.
From an international standpoint, a quick reminder that this month, there will be a PH meeting in Aswan, Egypt (18-19 October) organised by Sir Magdi Yacoub and featuring several PVRI and international PH speakers. This will be followed by the 1st International Symposium of Infection & Pulmonary Hypertension on 21-22 October (same venue).
From an educational standpoint, Martin Johnson and Colin Church, with the expert help of our Marketing Manager Aaron Shefras, are in the process of finalising the second phase of the PVRI Digital Clinic. This will include 9 additional clinical cases from various academic PH centres. Martin, Colin and Aaron are very proud to announce the launch of this PVRI activity at the upcoming Lima meeting, so stay fully tuned. We thank all specialists involved from various academic centres for their hard work in providing highly educational and challenging cases.
Some additional news just hot off the press! In the name of the entire PVRI community, I would like to warmly congratulate two of our very esteemed members. At the 2019 European Respiratory Society (ERS) International Congress held in Madrid, Spain, just a few days ago, Nick Morrell received the ERS Lifetime Achievement Award in Pulmonary Arterial Hypertension (PAH) and, Marc Humbert became ERS President Elect for 2020, which will give him the ERS President tenure for 2021-2022. Very highly deserved nominations for two of our pioneering leaders in the field.
In closing, I would like to wish you all a very productive new academic year. I hope to see you soon in Lima.